Exploration of Potential Genetic Biomarkers for Heart Failure: A Systematic Review

Abstract

Patients with heart failure (HF) often present with signs and symptoms that are often nonspecific and with a wide differential diagnosis, making diagnosis and prognosis of HF by clinical presentation alone challenging. Our knowledge on genetic diversity is rapidly evolving with high-throughput DNA sequencing technology, which makes a great potential for genetic biomarker development. The present review attempts to provide a comprehensive review on the modification of major genetic components in HF patients and to explore the potential application of these components as clinical biomarkers in the diagnosis and in monitoring the progress of HF. The literature search was conducted using six databases, resulting in the inclusion of eighteen studies in the review. The findings of these studies were summarized narratively. An appraisal of the reporting quality of the included studies was conducted using a twelve-item checklist adapted from the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist. The findings showed that changes in genetic components in patients with HF compared to healthy controls could be noninvasive diagnostic or prognostic tools for HF with higher specificity and sensitivity in comparison with the traditional biomarkers. This review provided evidence for the potential of developing genetic biomarkers of HF.

Integration of RNA molecules data with prior-knowledge driven Joint Deep Semi-Negative Matrix Factorization for heart failure study

“…NT-proBNP/BNP is an invasive diagnosis and may harm HF patients. Therefore, genes or other genetic material have emerged as an alternative non-invasive method for disease diagnosis ( Chair et al, 2021 ). In addition, genotypic biomarkers also provide potential targets for drug development.…”

A Set of Possible Markers for Monitoring Heart Failure and Cognitive Impairment Associated: A Review of Literature from the Past 5 Years

“…In addition, since biochemical biomarkers are the result of the expression of genetic biomarkers, much research has been carried out in this regard for the purpose of guidance on the diagnosis of cardiovascular diseases [51,52], drug therapy [53,54], to investigate tissue analysis and biochemical biomarkers [55][56][57], and heart-brain correlation itself [47].…”

Identification of hub genes in heart failure by integrated bioinformatics analysis and machine learning

“…However, HF patients typically present with non-specific signs and symptoms and have a wide range of differential diagnoses, making the diagnosis and prognosis of HF challenging based solely on clinical manifestations. Given the increasing prevalence of HF worldwide, timely treatment and management of this potentially fatal disease through various pharmacological and/or non-pharmacological means is crucial for patients (2). With the development of highthroughput sequencing, our understanding of genetic diversity is rapidly advancing, providing enormous potential for the development of genetic biomarkers.…”